Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Post by MasterAlgaeon Sep 10, 2020 11:23am

245 Views

Post# 31533229

No Buying

That somone selling 9,500 shares lowers the share price by 2.5% and reduces the market capitalization of ATE by almost 4million dollars is really quite something...especially since the bid and ask (market) represents $95.00 on an order that size.

I'd say that Stern IR got the better of ATE on the Investor Relation deal.

Since the announcement where we shareholders pay Stern $17,000 a month - the market capitalization of Antibe Therapeutics is down just shy of $20,000,000.00 and the volume has vanished.

Bullboard Posts

Anaergia expands relationship with PepsiCo